Your browser doesn't support javascript.
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng, Wang-Huei; Chang, Sui-Yuan; Lin, Pin-Hung; Hsieh, Ming-Ju; Chang, Hao-Hsiang; Cheng, Chien-Yu; Yang, Hung-Chih; Pan, Ching-Fu; Ieong, Si-Man; Chao, Tai-Ling; Chen, Jang-Pin; Cheng, Shu-Hsing; Chang, Shan-Chwen.
  • Sheng WH; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Chang SY; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Lin PH; Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Hsieh MJ; Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan; Occupational Safety and Health Office, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang HH; Department of Family Medicine, National Taiwan University Hospital and College of Medicine, Taipei 10016, Taiwan.
  • Cheng CY; Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University, Taiwan.
  • Yang HC; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Pan CF; Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Ieong SM; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Chao TL; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Chen JP; Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.
  • Cheng SH; Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University, School of Public Health, Taipei Medical University, Taipei, Taiwan.
  • Chang SC; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan. Electronic address: changsc@ntu.edu.tw.
J Formos Med Assoc ; 121(4): 766-777, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1882193
ABSTRACT
BACKGROUND/

PURPOSE:

Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited.

METHODS:

We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines. Four groups of prime-boost vaccination schedules were designed Group 1, ChAdOx1/ChAdOx1 8 weeks apart; Group 2, ChAdOx1/mRNA-1273 8 weeks apart; Group 3, ChAdOx1/mRNA-1273 4 weeks apart; and Group 4, mRNA-1273/mRNA-1273 4 weeks apart. The primary outcome was serum anti-SARS-CoV-2 IgG titers and neutralizing antibody titers against B.1.1.7 (alpha) and B.1.617.2 (delta) variants on day 28 after the second dose. Adverse events were recorded up until 84 days after the second dose.

RESULTS:

We enrolled 399 participants with a median age of 41 years and 75% were female. On day 28 after the second dose, the anti-SARS-CoV-2 IgG titers of both heterologous vaccinations (Group 2 and Group 3) were significantly higher than that of homologous ChAdOx1 vaccination (Group 1), and comparable with homologous mRNA-1273 vaccination (Group 4). The heterologous vaccination group had better neutralizing antibody responses against the alpha and delta variant as compared to the homologous ChAdOx1 group. Most of the adverse events (AEs) were mild and transient. AEs were less frequent when heterologous boosting was done at 8 weeks rather than at 4 weeks.

CONCLUSION:

Heterologous ChAdOx1/mRNA-1273 vaccination provided higher immunogenicity than homologous ChAdOx1 vaccination and comparable immunogenicity with the homologous mRNA-1273 vaccination. Our results support the safety and efficacy of heterologous prime-boost vaccination using the ChAdOx1 and mRNA-1273 COVID-19 vaccines. (ClinicalTrials.gov number, NCT05074368).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Female / Humans Language: English Journal: J Formos Med Assoc Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: J.jfma.2022.02.020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Female / Humans Language: English Journal: J Formos Med Assoc Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: J.jfma.2022.02.020